UNSPSC 51162602: Bibenzonium

This classification denotes an antitussive agent with the molecular structure C19H26NO, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier, 34YTZ517S2 chemically known as (2-(1,2-diphenylethoxy)ethyltrimethyl)ammonium, but more commonly known as bibenzonium, which bears US NIH Compound Identifier 71954. European Medicines Agency schedules Bibenzonium in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00798MIG. As of Q4 2014, BIBENZONIUM remains US FDA's Preferred Term for this commodity.

Bibenzonium bears US NLM identifiers UMLS ID C2347006 and NCI Concept Code C73821. SMILES: O(CC[N](C)(C)C)C(CC1CCCCC1)C1CCCCC1.

UNSPSC 51162602 Bibenzonium, a Commodity code, encompasses pharmaceutical products and drug-related supplies that state and local governments procure for public health and emergency response programs. Recent solicitations under this code show state and local buyers acquiring naloxone (an opioid antagonist), safe drug deactivation systems, and multi-source generic pharmaceuticals distributed through cooperative purchasing frameworks. The issuing bodies include county health departments and state-administered cooperative purchasing alliances that aggregate demand across multiple participating jurisdictions and states. Work solicited ranges from direct product procurement with specified unit volumes and quarterly delivery schedules to framework agreements establishing pricing and supply relationships with authorized pharmaceutical wholesalers.

Seminole County, Florida posted an IFB (solicitation IFB60459723LAS) on June 30, 2026, requesting 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the County Community Health Building, response due July 26, 2023. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued an RFP (S1070000015802) on January 20, 2026, to establish multiple contracts for generic multi-source pharmaceuticals and OTC products serving participating state and local facilities, including Oregon, with responses due March 26, 2026. Both solicitations require vendors to meet FDA compliance, cGMP certification where applicable, and state-specific insurance and employment verification standards. Geographic activity centers on Florida and the upper Midwest (Minnesota and partner states in MMCAP), with the cooperative purchasing vehicle extending reach across multiple jurisdictions within participating states.